Table 1.

Characteristics of the Sample, According to Anti-apoA-1 IgG Status

Total Sample (n=5220)Anti-apoA-1 IgGP Value
Absence (n=4180)Presence (n=1040)
Age, y52.7±10.752.2±10.70.184
Male sex, n (%)1985 (47.5)488 (46.9)0.744
History of CAD, n (%)146 (3.5)43 (4.1)0.321
Current smoking, n (%)1086 (26.0)272 (26.2)0.909
Diabetes mellitus, n (%)276 (6.6)58 (5.6)0.226
Hypertension, n (%)1389 (33.23)349 (33.6)0.841
Autoimmune disease, n (%)88 (2.1)32 (3.1)0.061
Body mass index, kg/m225.6±4.425.7±4.60.712
Total cholesterol, mmol/L5.58±1.025.50±1.030.022
HDL cholesterol, mmol/L1.64±0.431.62±0.460.250
LDL cholesterol, mmol/L3.33±0.903.27±0.920.068
Triglycerides, mmol/L1.38±1.121.36±1.220.663*
SCORE CV risk categories, n (%)
 Low risk2507 (60.1)643 (62.0)
 Intermediate risk1160 (27.8)269 (25.9)
 High risk311 (7.4)83 (8.0)
 Very high risk196 (4.7)43 (4.1)0.487
CV drugs, n (%)
 Aspirin684 (16.4)160 (15.4)0.443
 Statins446 (10.7)98 (9.4)0.239
 Beta blockers212 (5.1)70 (6.7)0.034
 Calcium-channel blockers120 (2.9)33 (3.2)0.605
 ACEi/ARB511 (12.2)124 (11.9)0.354
 Diuretics80 (1.9)19 (1.8)0.854
 Incident CAD rates, n (%)117 (2.8)40 (3.9)0.077
 Nonfatal, n (%)95 (2.3)37 (3.6)0.018
 Fatal, n (%)22 (0.5)3 (0.3)0.320
  • Data are expressed as mean±standard deviation or number of participants and (percentage). ACEi indicates angiotensin-converting enzyme inhibitor; Anti-apoA-1 IgG, anti-apolipoprotein A-1 autoantibodies; ARB, angiotensin receptor blockers; CAD, coronary artery disease; CV, cardiovascular; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SCORE, Systematic Coronary Risk Evaluation.

  • * Statistical analysis for continuous variables by student’s t test or Mann–Whitney test depending on the normality assumption. Statistical analysis for categorical variables by the χ2 test.